ISR IsoRay

Isoray To Announce Second Quarter Fiscal 2020 Financial Results on February 11, 2020

Isoray To Announce Second Quarter Fiscal 2020 Financial Results on February 11, 2020

Conference Call is Tuesday, February 11, 2020 at 4:30 p.m. ET/1:30 p.m. PT

RICHLAND, Wash., Jan. 31, 2020 (GLOBE NEWSWIRE) -- (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it will host a conference call to discuss its financial results for the second quarter fiscal 2020 ended December 31, 2019 on Tuesday, February 11, 2020, at 4:30 p.m. Eastern Time. The Company will issue a press release announcing its financial results for the second quarter fiscal 2020 after the close of the U.S. stock markets on February 11, 2020. 

To listen to the conference call, please dial 844-602-0380. For callers outside the U.S., please dial 862-298-0970.

The conference call will be simultaneously webcast and can be accessed at . The webcast will be available until May 11, 2020 following the conference call. A replay of the call will also be available by phone and can be accessed by dialing 877-481-4010 and providing reference number 58363. For callers outside the U.S., please dial 919-882-2331 and provide reference number 58363. The replay will be available beginning approximately 1 hour after the completion of the live event, ending at 4:30 pm Eastern Time on February 18, 2020.

About Isoray

Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting . Join us on and follow us on Twitter

Contact
Investor Relations: Mark Levin (501) 255-1910
Media and Public Relations: Sharon Schultz (302) 539-3747
EN
31/01/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IsoRay

 PRESS RELEASE

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Pr...

Perspective Therapeutics Announces Acceptance of VMT-α-NET Data for Presentation at the ASCO Gastrointestinal Cancers Symposium SEATTLE, Dec. 04, 2025 (GLOBE NEWSWIRE) --  (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that updated data on the Company’s [212Pb]VMT-α-NET program have been accepted for presentation at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium () Congress 2026 taking place from January 8 to 10, 2026 in San Franc...

David Nierengarten ... (+9)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Thomas Yip
  • Yun Zhong
 PRESS RELEASE

Perspective Therapeutics to Participate in Upcoming December Conferenc...

Perspective Therapeutics to Participate in Upcoming December Conferences SEATTLE, Nov. 20, 2025 (GLOBE NEWSWIRE) -- November 20, 2025 –  ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments for cancers throughout the body, today announced that members of its senior leadership team will participate in and be available for one-on-one meetings with investors at the following upcoming conferences: Piper Sandler & Co. 37th Annual Healthcare Conference – Fireside ChatDate: Tuesday, December 2, 2025Time: 1:00 - 1:25 p....

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan

ResearchPool Subscriptions

Get the most out of your insights

Get in touch